Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058753 | 1.00 | KDM1A (0.46) | KDM1ACYP2C9ELANEMAPTALDH1A1 | |
| SCHEMBL4063867 | 0.91 | CYP2C9 (0.56) | KDM1ACYP2C9ELANEMAPTALDH1A1 | |
| SCHEMBL4063870 | 0.91 | CYP2C9 (0.56) | KDM1ACYP2C9ELANEMAPTALDH1A1 | |
| SCHEMBL4055221 | 0.85 | ELANE (0.60) | KDM1ACYP2C9ELANEMAPTALDH1A1 | |
| SCHEMBL20805906 | 0.85 | CYP2C9 (0.50) | CYP2C9MAPTALDH1A1LMNARAB9A | |
| SCHEMBL23635384 | 0.84 | CYP2C9 (0.47) | CYP2C9ELANEMAPTALDH1A1LMNA | |
| SCHEMBL8302303 | 0.84 | CYP2C9 (0.49) | CYP2C9MAPTALDH1A1LMNARAB9A | |
| SCHEMBL9187465 | 0.82 | KMT2A (0.49) | CYP2C9MAPTALDH1A1LMNARAB9A | |
| SCHEMBL9187472 | 0.82 | KMT2A (0.49) | CYP2C9MAPTALDH1A1LMNARAB9A | |
| SCHEMBL10483925 | 0.82 | CYP2C9 (0.48) | CYP2C9MAPTALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534547-B2 | Optically active compound and photosensitive resin composition | OSAKA GAS COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | KDM1A 113/4885CYP2C9 1479/4885ELANE 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.